Skip to main content

New Combination Approaches To Enhance Rituximab Based Lymphoma Therapies

In Order to Read Online or Download New Combination Approaches To Enhance Rituximab Based Lymphoma Therapies Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies Book
Author : Anonim
Publisher : Academic Press
Release : 2020-11-01
ISBN : 0128167378
Language : En, Es, Fr & De

GET BOOK

Book Description :

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas Book
Author : Ana C. Xavier,Mitchell S. Cairo
Publisher : Springer Nature
Release : 2019-09-13
ISBN : 3030244245
Language : En, Es, Fr & De

GET BOOK

Book Description :

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

The Lymphoid Neoplasms 3ed

The Lymphoid Neoplasms 3ed Book
Author : Ian Magrath
Publisher : CRC Press
Release : 2010-07-30
ISBN : 1444113224
Language : En, Es, Fr & De

GET BOOK

Book Description :

This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors synthesise for the reader apsects of current knowledge and likely future developments, and direct them to the appropriate resources should they wish to pursue particular avenues of scientific or literature research.

Living with Lymphoma

Living with Lymphoma Book
Author : Elizabeth M. Adler
Publisher : JHU Press
Release : 2005-09-30
ISBN : 0801881803
Language : En, Es, Fr & De

GET BOOK

Book Description :

When neurobiologist Elizabeth M. Adler was diagnosed with non-Hodgkin's lymphoma, she learned everything she could about the disease. In "Living with Lymphoma," she combines her knowledge of lymphoma--both scientific and personal--with the desire to help other patients come to grips with this complex, and often baffling, disease. Readers gain sufficient background to understand and evaluate medical literature, and to ask their physicians questions specific to their own needs.

Perry s The Chemotherapy Source Book

Perry s The Chemotherapy Source Book Book
Author : Michael C. Perry,Donald C. Doll,Carl E. Freter
Publisher : Lippincott Williams & Wilkins
Release : 2012-07-30
ISBN : 1469803437
Language : En, Es, Fr & De

GET BOOK

Book Description :

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Lymphoma New Insights for the Healthcare Professional 2012 Edition

Lymphoma  New Insights for the Healthcare Professional  2012 Edition Book
Author : Anonim
Publisher : ScholarlyEditions
Release : 2012-12-10
ISBN : 1464970351
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lymphoma: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Lymphoma. The editors have built Lymphoma: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lymphoma: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Biotargets of Cancer in Current Clinical Practice

Biotargets of Cancer in Current Clinical Practice Book
Author : Mauro Bologna
Publisher : Springer Science & Business Media
Release : 2012-04-03
ISBN : 1617796158
Language : En, Es, Fr & De

GET BOOK

Book Description :

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.

Lymphoma New Insights for the Healthcare Professional 2011 Edition

Lymphoma  New Insights for the Healthcare Professional  2011 Edition Book
Author : Anonim
Publisher : ScholarlyEditions
Release : 2012-01-09
ISBN : 1464900949
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lymphoma: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Lymphoma. The editors have built Lymphoma: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lymphoma: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Hemic and Lymphatic Diseases New Insights for the Healthcare Professional 2013 Edition

Hemic and Lymphatic Diseases  New Insights for the Healthcare Professional  2013 Edition Book
Author : Anonim
Publisher : ScholarlyEditions
Release : 2013-07-22
ISBN : 1481659243
Language : En, Es, Fr & De

GET BOOK

Book Description :

Hemic and Lymphatic Diseases: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Hemic and Lymphatic Diseases: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Hemic and Lymphatic Diseases: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy Book
Author : Patrik Andersson,Christian Ostheimer
Publisher : Frontiers Media SA
Release : 2019-12-27
ISBN : 2889631613
Language : En, Es, Fr & De

GET BOOK

Book Description :

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Developing Costimulatory Molecules for Immunotherapy of Diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases Book
Author : Manzoor Ahmad Mir
Publisher : Academic Press
Release : 2015-05-25
ISBN : 0128026758
Language : En, Es, Fr & De

GET BOOK

Book Description :

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Sherlock s Diseases of the Liver and Biliary System

Sherlock s Diseases of the Liver and Biliary System Book
Author : James S. Dooley,Anna S. F. Lok,Guadalupe Garcia-Tsao,Massimo Pinzani
Publisher : John Wiley & Sons
Release : 2018-06-08
ISBN : 1119237645
Language : En, Es, Fr & De

GET BOOK

Book Description :

A new, fully updated edition of the world’s most famous book on liver diseases—with updating of all areas and inclusion of new specific topics, by internationally renowned specialists This brand new edition of the classic book on hepatology provides a concise, clearly presented and well-structured review across the whole spectrum of hepatobiliary diseases by some of the world’s leading hepatologists and hepatobiliary specialists. Where many other hepatology textbooks provide detailed accounts of basic science and clinical management, Sherlock's Diseases of the Liver and Biliary System, 13th Edition takes a different approach. Concentrating on the clinical decisions to be taken and the relevant supporting data, it is written and edited to maintain Sheila Sherlock's unique approach, in particular the clarity and layout of the text, and the explanatory figures and tables. The book is thus concise, highly accessible, and generously illustrated with over 700 attractive color figures. There is a pithy approach to each disease based both on evidence and on the authors’ experience, the hallmark of this book. Based on these elements, the 12th edition was awarded first prize in the 2012 British Medical Association Book Awards in the Internal Medicine category. Sherlock's Diseases of the Liver and Biliary System begins by introducing the anatomy and function of the liver to readers, continuing then with in-depth coverage of liver biopsy techniques and interpretation, and fibrogenesis and its assessment. There are then chapters on all aspects of liver and biliary disease including acute liver failure, cirrhosis, portal hypertension, hepatic encephalopathy, ascites, hepatitis B and C, alcohol and the liver, non-alcoholic fatty liver disease, drug related liver reactions, cholestatic, autoimmune and genetic liver diseases, benign and malignant tumours and not least liver transplantation. There are also chapters on the liver in pregnancy, in the neonate, infancy and childhood, in systemic diseases and in infections. This new edition also features four new individual chapters focusing on coagulation, non-invasive assessment of fibrosis and cirrhosis; vascular diseases of the liver and portal vein thrombosis, and nutrition in liver disease. Digital downloads of the figures from this edition are offered on a companion website. Internationally recognized and loved, world-renowned hepatology book, first published in 1955 Takes a one-of-a-kind, clinical approach maintaining Sheila Sherlock’s clarity and legacy of presentation Full colour throughout with 700 illustrative figures Wide faculty of international contributors Sherlock's Diseases of the Liver and Biliary System, 13th Edition is an ideal primer in hepatology for students and trainees in hepatology and gastroenterology, and a valuable resource for all specialist gastroenterologists and hepatologists, paediatricians, pathologists, radiologists, general physicians and specialist nurses.

Novel Immunotherapeutic Approaches to the Treatment of Cancer

Novel Immunotherapeutic Approaches to the Treatment of Cancer Book
Author : Paul D. Rennert
Publisher : Springer
Release : 2016-05-30
ISBN : 3319298275
Language : En, Es, Fr & De

GET BOOK

Book Description :

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Lymphoma Pathology Diagnosis and Treatment

Lymphoma  Pathology  Diagnosis and Treatment Book
Author : Robert Marcus,John W. Sweetenham,Michael E. Williams
Publisher : Cambridge University Press
Release : 2007-06-21
ISBN : 9780521865449
Language : En, Es, Fr & De

GET BOOK

Book Description :

Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.

Treatment of Cancer

Treatment of Cancer Book
Author : Pat Price,Karol Sikora
Publisher : CRC Press
Release : 2020-11-24
ISBN : 0429651643
Language : En, Es, Fr & De

GET BOOK

Book Description :

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Immunogenic Cell Death in Cancer From Benchside Research to Bedside Reality

Immunogenic Cell Death in Cancer  From Benchside Research to Bedside Reality Book
Author : Abhishek D Garg,Patrizia Agostinis
Publisher : Frontiers Media SA
Release : 2016-04-29
ISBN : 2889198383
Language : En, Es, Fr & De

GET BOOK

Book Description :

Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Hodgkin s and Non Hodgkin s Lymphoma

Hodgkin s and Non Hodgkin s Lymphoma Book
Author : John P. Leonard,Morton Coleman
Publisher : Springer Science & Business Media
Release : 2008-03-05
ISBN : 9780387293462
Language : En, Es, Fr & De

GET BOOK

Book Description :

In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity. In this volume an internationally recognized group of experts review relevant aspects of the biology, diagnosis and management, with particular emphasis on the emerging data available for this disease.

Clinical Radiation Oncology E Book

Clinical Radiation Oncology E Book Book
Author : Leonard L. Gunderson,Joel E. Tepper
Publisher : Elsevier Health Sciences
Release : 2011-09-16
ISBN : 1455726036
Language : En, Es, Fr & De

GET BOOK

Book Description :

With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities! Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors –many of whom are new to this edition – affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines.

Non Hodgkin Lymphoma

Non Hodgkin Lymphoma Book
Author : Andrew M. Evens,Kristie A. Blum
Publisher : Springer
Release : 2015-02-06
ISBN : 3319131508
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.

Dry Mouth The Malevolent Symptom

Dry Mouth  The Malevolent Symptom Book
Author : Leo M. Sreebny,Arjan Vissink
Publisher : John Wiley & Sons
Release : 2010-02-25
ISBN : 9780813820972
Language : En, Es, Fr & De

GET BOOK

Book Description :

Xerostomia, more commonly called dry mouth, affects anestimated 20 percent of adults worldwide and can severelydiminish one’s quality of life. Dry Mouth, theMalevolent Symptom: A Clinical Guide relies on evidence-basedresearch to provide an introductory primer on oral dryness and themodalities available to treat it. The book describes thevaried etiology of the disease, but emphasizes clinicalprotocols and step-by-step procedures for diagnosis and treatmentplanning. Dry Mouth is a user-friendly manual guiding cliniciansthrough identifying and managing this common condition. Causesincluding radiotherapy, chemotherapy, systemic diseases,polypharmacy, and the natural progression of aging are discussed inconjunction with the clinical symptoms and signs associated witheach one. Multiple avenues for treatment are presented,highlighting salivary stimulation and supplementation techniques,pharmacologic aids, and critically required oral therapy. Althoughintended primarily for the professionals that treat those affectedby xerostomia, Dry Mouth may also be of interest tosufferers of this condition.